Blood Clot News and Research

RSS

A Blood Clot is a mass of blood that forms when blood platelets, proteins, and cells stick together. When a blood clot is attached to the wall of a blood vessel, it is called a thrombus. When it moves through the bloodstream and blocks the flow of blood in another part of the body, it is called an embolus.

Reperfusion therapy proves beneficial for patients with heart attacks

The wider use of reperfusion therapy in patients with heart attack (AMI) can save millions of lives in Europe. Effective reperfusion therapy in an AMI patient can cut the individual risk of dying by half.

1 Sep 2009

Warfarin therapy provides substantial protection for elder patients with atrial fibrillation

Warfarin (an oral anticoagulant) therapy for patients with atrial fibrillation - the most common type of significant heart rhythm disorder - appears to be most beneficial for the oldest patients, for those who have had a prior stroke and for patients with multiple risk factors for stroke, according to a new study by Kaiser Permanente and Massachusetts General Hospital researchers.

1 Sep 2009

Cordis enrolls first patient in the CYPRESS clinical study

Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that the first patient has been enrolled in the CYPRESS study, which will assess clinical outcomes in a broad range of patients with coronary artery disease who take dual anti-platelet therapy after receiving a CYPHER Sirolimus-eluting Coronary Stent. The procedure was performed by Patrick Flaherty, D.O., Arkansas Heart Hospital in Little Rock, AK.

31 Aug 2009

Health Net urges Americans to have their blood cholesterol measured

Tomorrow, September 1, marks the start of National Cholesterol Education Month. In support of this educational effort, Health Net, Inc., (NYSE: HNT) is encouraging those who haven't yet done so, to have their blood cholesterol measured and, if it's high, to embark on a cholesterol-lowering program.

31 Aug 2009

Oral dabigatran etexilate reduces the risk of stroke and systemic embolism

Boehringer Ingelheim today announced data from the landmark RE-LY® study - the largest atrial fibrillation (AF) outcomes trial ever conducted (18,113 patients in 44 countries worldwide) - presented for the first time at the European Society of Cardiology Congress and published online in the New England Journal of Medicine. Results show that dabigatran etexilate 150mg BID significantly reduces the risk of stroke and systemic embolism by 34% (p<0.001) in patients with atrial fibrillation compared to well-controlled warfarin without increasing the risk of major bleeding.

31 Aug 2009

European Medicines Agency accepts reviewal of Merck's MAA for regulatory approval of vernakalant IV

Merck & Co., Inc., Whitehouse Station, NJ, USA, which operates in many countries as Merck Sharp & Dohme Limited, announced today that the European Medicines Agency (EMEA) accepted for review the Company’s Marketing Authorisation Application (MAA) for regulatory approval of vernakalant intravenous (IV).

27 Aug 2009

Optimum Lightpath chosen as telecommunications provider by Medical Arts Radiology

Optimum Lightpath(SM), a market leader in Ethernet-based communication solutions for New York metropolitan area businesses, today announced that Medical Arts Radiology, one of the largest medical imaging groups in Long Island, has selected Optimum Lightpath as its telecommunications provider.

26 Aug 2009

Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

Amgen today announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia and type-2 diabetes (the Trial to Reduce Cardiovascular Endpoints with Aranesp((R)) Therapy, or TREAT), treatment of anemia with Aranesp((R) )(darbepoetin alfa) to a hemoglobin target of 13 g/dL had no statistically significant effect on either of two primary endpoints compared with placebo treatment.

26 Aug 2009

New online educational forum for medical professionals from HMP Communications

HMP Communications, the authoritative source for education services targeting healthcare professionals for over two decades, announced it has added a new online educational forum at www.CardiovascularLIVE.com. The site offers video instruction and discussion forums for medical professionals.

26 Aug 2009

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that study results demonstrated that arimoclomol exhibited both statistically significant neuroprotective and neuroregenerative effects in brain cells of animals induced with stroke, offering important insights into this drug candidate’s mechanism of action.

25 Aug 2009

Portola Pharmaceuticals' investigational antiplatelet drug elinogrel featured at the ESC Congress 2009

Portola Pharmaceuticals, Inc. today announced two oral presentations at the European Society of Cardiology (ESC) Congress 2009 in Barcelona, Spain, that will feature its investigational antiplatelet drug elinogrel, a P2Y12 ADP receptor antagonist that is currently in Phase II clinical development with Novartis, Portola's development and commercialization partner.

25 Aug 2009

Thick blood to cause or prevent strokes and heart attacks proved by scientists

"Thick" blood can cause heart attack and stroke, but also prevent them. Scientists at Heidelberg University Hospital have explained the mechanism of this clinical paradox for the first time on an animal model. Mice with a greater tendency to form blood clots have larger plaques in their vessels, but they are more stable.

24 Aug 2009

Mount Sinai Medical Center physicians pioneer a non-surgical procedure for treating LAA

Physicians at The Mount Sinai Medical Center were the first in the country to perform a non-surgical procedure using sutures to tie off a left atrial appendage (LAA), which is the source of blood clots leading to stroke in patients with atrial fibrillation (AFib). AFib is the most common sustained heart-rhythm disorder in the United States.

24 Aug 2009

Endologix publishes abdominal aortic aneurysm treatment trial results online

Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today the online publication of results from the pivotal prospective, multicenter clinical trial of the Company's Powerlink XL((R)) System for treatment of abdominal aortic aneurysm in large diameter proximal aortic necks.

21 Aug 2009

Angiotech Pharmaceuticals plans US launch of Option Inferior Vena Cava Filter

Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP), today announced the commercial launch of the Option(TM) Inferior Vena Cava (IVC) Filter in the United States, following FDA 510(k) clearance in June and a limited pre-launch in July. Angiotech holds exclusive worldwide rights to market and distribute the Option IVC Filter, which it obtained in a license agreement with privately held Rex Medical, LP (Rex Medical), as announced in March 2008.

20 Aug 2009

Scientists grow new blood vessels to combat heart disease

Although open-heart surgery is a frequent treatment for heart disease, it remains extremely dangerous. Now groundbreaking research from Dr. Britta Hardy of Tel Aviv University's Sackler School of Medicine has shown the potential for an injected protein to regrow blood vessels in the human heart ― eliminating the need for risky surgery altogether.

13 Aug 2009

New type of anti-clotting drug called Apixaban

The dean of the University of Oklahoma College of Public Health and a team of scientists worldwide have found a better way to prevent deadly blood clots after joint replacement surgery - a major problem that results in thousands of unnecessary deaths each year. The research appears this week in the New England Journal of Medicine.

11 Aug 2009

Complex, eight-hour open procedure removes life-threatening blood clots from 17-year-old's lungs

After visiting the emergency room with fainting spells and shortness of breath, a 17-year-old Morningside Heights boy was diagnosed with rare, life-threatening blood clots blocking his pulmonary arteries. To address the problem, surgeons at NewYork-Presbyterian Hospital Morgan Stanley Children's Hospital successfully performed a pulmonary thromboendartectomy (PTE) surgery -- reportedly, the first time it has been performed on a child in the New York City area.

6 Aug 2009

Protein unfolding key to understanding blood clot mechanics

Fibrin, the chief ingredient of blood clots, is a remarkably versatile polymer. On one hand, it forms a network of fibers -- a blood clot -- that stems the loss of blood at an injury site while remaining pliable and flexible. On the other hand, fibrin provides a scaffold for thrombi, clots that block blood vessels and cause tissue damage, leading to myocardial infarction, ischemic stroke, and other cardiovascular diseases. How does fibrin manage to be so strong and yet so extensible under the stresses of healing and blood flow?

6 Aug 2009

Emergency physicians should trust their judgment on chest pain symptoms

Their research suggests that emergency physicians should counsel with other physicians against discharge when they feel strongly about a patient for whom there is no compelling data, other than our evaluation and judgment, Chandra said.

4 Aug 2009

Blood Clot News and Research

Further Reading

Reperfusion therapy proves beneficial for patients with heart attacks

Warfarin therapy provides substantial protection for elder patients with atrial fibrillation

Cordis enrolls first patient in the CYPRESS clinical study

Health Net urges Americans to have their blood cholesterol measured

Oral dabigatran etexilate reduces the risk of stroke and systemic embolism

European Medicines Agency accepts reviewal of Merck's MAA for regulatory approval of vernakalant IV

Optimum Lightpath chosen as telecommunications provider by Medical Arts Radiology

Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

New online educational forum for medical professionals from HMP Communications

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

Portola Pharmaceuticals' investigational antiplatelet drug elinogrel featured at the ESC Congress 2009

Thick blood to cause or prevent strokes and heart attacks proved by scientists

Mount Sinai Medical Center physicians pioneer a non-surgical procedure for treating LAA

Endologix publishes abdominal aortic aneurysm treatment trial results online

Angiotech Pharmaceuticals plans US launch of Option Inferior Vena Cava Filter

Scientists grow new blood vessels to combat heart disease

New type of anti-clotting drug called Apixaban

Complex, eight-hour open procedure removes life-threatening blood clots from 17-year-old's lungs

Protein unfolding key to understanding blood clot mechanics

Emergency physicians should trust their judgment on chest pain symptoms

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News